BioCentury
ARTICLE | Finance

Modis’ mitochondrial modification

How early clinical data enabled Modis to raise $30M series A for mitochondrial program

October 5, 2018 4:04 PM UTC

Compassionate use data from its lead program enabled rare genetic disease company Modis Therapeutics Inc. to attract $30 million in series A funding co-led by F-Prime Capital Partners and OrbiMed Advisors.

Founding investor Aceras Life Sciences and new investor Osage University Partners also joined the round, which closed on Oct. 1...

BCIQ Company Profiles

Modis Therapeutics Inc.